Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma.
We report a response to pazopanib in a 69-year-old man with heavily pre-treated metastatic extraosseous Ewing sarcoma in addition to molecular profiling of his tumor. To our knowledge, this case is the earliest to demonstrate activity of an oral multi-targeted kinase inhibitor in Ewing sarcoma. This case provides rationale for adding a Ewing sarcoma arm to SARC024, a phase II study of regorafenib, another multi-targeted kinase inhibitor, in patients with liposarcoma, osteosarcoma and Ewing and Ewing-like sarcomas (NCT02048371). This national multi-institutional study is ongoing.
Mayo Clinic , Jacksonville, FL, USA.
Steven
S
Attia
Mayo Clinic , Rochester, MN, USA.
Scott H
SH
Okuno
Mayo Clinic , Rochester, MN, USA.
Steven I
SI
Robinson
3Aurora Healthcare , Milwaukee, WI, USA.
Nicholas P
NP
Webber
4University of Florida , Jacksonville, FL, USA.
Daniel J
DJ
Indelicato
Royal Marsden Hospital , London, UK.
Robin L
RL
Jones
Royal Marsden Hospital , London, UK.
Sanjay P
SP
Bagaria
Mayo Clinic , Jacksonville, FL, USA.
Robin L
RL
Jones
Mayo Clinic , Jacksonville, FL, USA.
Courtney
C
Sherman
Mercy Medical Center , Janesville, WI, USA.
Kevin R
KR
Kozak
Mayo Clinic , Jacksonville, FL, USA.
Cherise M
CM
Cortese
University of Wisconsin , Madison, WI, USA.
Thomas
T
McFarland
University of Miami , FL, USA.
Jonathan C
JC
Trent
Mount Sinai Medical Center , New York, NY, USA.
Robert G
RG
Maki
Ewing; pazopanib; sarcoma